REGN 1154

Drug Profile

REGN 1154

Alternative Names: REGN-1154

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 30 Jan 2014 Phase-I development is ongoing
  • 25 Jan 2013 Regeneron Pharmaceuticals completes enrolment in its phase I trial in Healthy volunteers in Australia (NCT01540539)
  • 31 Mar 2012 Phase-I clinical trials in Undefined indication in Australia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top